Debt to Equity Ratio: A measure of a company's financial leverage calculated by dividing its long-term debt by shareholders equity. Calculated as: Total Debt / Shareholders Equity
SAB Biotherapeutics, Inc. (SABS) had Debt to Equity Ratio of 0.14 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$1.32M |
|
$-34.11M |
|
-- |
|
$1.32M |
|
$44.23M |
|
$-42.91M |
|
$8.81M |
|
$-34.11M |
|
$-34.11M |
|
$-34.11M |
|
$-34.11M |
|
$-34.11M |
|
$-34.11M |
|
$-42.91M |
|
$-38.35M |
|
9.26M |
|
9.26M |
|
$-3.68 |
|
$-3.68 |
|
| Balance Sheet Financials | |
$23.79M |
|
$15.37M |
|
$20.40M |
|
$44.20M |
|
$7.98M |
|
$3.28M |
|
$10.25M |
|
$18.23M |
|
$25.97M |
|
$25.97M |
|
$25.97M |
|
9.29M |
|
| Cash Flow Statement Financials | |
$-34.29M |
|
$-11.96M |
|
$-1.17M |
|
$56.57M |
|
$8.90M |
|
$-47.67M |
|
$2.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.98 |
|
-- |
|
-- |
|
0.11 |
|
|
Debt to Equity Ratio |
0.14 |
100.00% |
|
-3244.87% |
|
-3244.87% |
|
-2900.39% |
|
-2579.03% |
|
-2579.03% |
|
$-34.63M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
24.06 |
|
15.17 |
|
-131.33% |
|
-131.33% |
|
-77.17% |
|
-116.62% |
|
$2.80 |
|
$-3.74 |
|
$-3.70 |
|